Breaking News, Trials & Filings

NeoStem Completes Enrollment in CV Trial

Autologous stem cell treatment could reduce post-heart attack costs healthcare burden

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

NeoStem, Inc. has completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blind placebo-controlled Phase II trial testing AMR-001, an autologous adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). With infusion of the target population of 160 patients complete, NeoStem expects data readout in 3Q14. STEMI is the most dangerous type of myocardial infarction and is d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters